Heather M Fitzgerald (Heather Fitzgerald)

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 5

Top Topics

Machine Learning

Bipolar Disorder

Patient Reported Outcomes

Top Venues

Neuropsychiatric disease and treatment

Journal of medical economics

Patient preference and adherence

This page only lists publications with an associated author ORCID identifier.

Publications

Matthew Harlin, Craig Chepke, Frank Larsen, Karimah S Bell Lynum, Sanjeda R Chumki, Heather M Fitzgerald, Pedro Such, Jessica-McDonough Madera, Murat Yildirim, Moeen Panni, Stephen R Saklad
Aripiprazole Plasma Concentrations Delivered from Two 2-Month Long-Acting Injectable Formulations: An Indirect Comparison. Neuropsychiatric disease and treatment 19 (2023)
Heidi C Waters, Robert Stellhorn, Maëlys Touya, Heather M Fitzgerald, Sandipan Bhattacharjee, Citrome Leslie
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics 26 (1) (2023)
John F P Bridges, Joseph F Goldberg, Heather M Fitzgerald, Sanjeda R Chumki, Kathleen Beusterien, Oliver Will, Citrome Leslie
Prioritizing Treatment Goals of People Diagnosed with Bipolar I Disorder in the US: Best-Worst Scaling Results. Patient preference and adherence 17 (2023)
Heidi C Waters, Robert Stellhorn, Maëlys Touya, Heather M Fitzgerald, Sandipan Bhattacharjee, Citrome Leslie
The effects of early initiation of aripiprazole once-monthly on healthcare resource utilization and healthcare costs in individuals with schizophrenia: real-world evidence from US claims data. Journal of medical economics (2023)
Heather M Fitzgerald, Jason Shepherd, Hollie Bailey, Mia Berry, Jack Wright, Maxine Chen
Treatment Goals in Schizophrenia: A Real-World Survey of Patients, Psychiatrists, and Caregivers in the United States, with an Analysis of Current Treatment (Long-Acting Injectable vs Oral Antipsychotics) and Goal Selection. Neuropsychiatric disease and treatment 17 (2021)